While TERT promoter mutation showed a poor survival prognosis in glioma patients, O6-methylguanine-DNA methyltransferase (MGMT) methylation has long been recognized as an important factor in treatment decisions [7], and is also a positive prognostic factor [8–12]. The gene discussed is MGMT; the disease is central nervous system cancer.